Lymphatica Medtech, a clinical-stage company based in Lausanne, Switzerland, has successfully closed a €17.9 million Series B funding round to advance its innovative treatment for lymphedema.
The funding will primarily support the clinical development and validation of LymphoDrain, an implantable device that aims to revolutionize the management of lymphedema.
LymphoDrain is designed to address the significant unmet medical need for effective relief from lymphedema by restoring the lymphatic drainage function locally and actively.
The funding round was co-led by prominent investors including Panakès Partners, TechWald Next S.p.A., and CDP Venture Capital’s Digital Transition Fund. Additional participation came from OCCIDENT, Zürcher Kantonalbank, and Club Degli Investitori, alongside existing investors such as High-Tech Gründerfonds (HTGF).
Investors and board members have expressed confidence in Lymphatica's mission to address the unmet medical need for lymphedema treatment. The technology has the potential to transform patient care and improve outcomes significantly.
The LymphoDrain device has shown promising results in a pilot feasibility study, indicating its potential to significantly improve the quality of life for lymphedema patients.
The investment secured in this funding round will allow the company to continue refining the device and bringing it to market. Lymphatica Medtech's commitment to addressing a critical healthcare challenge reflects a growing trend in the medical technology sector.